Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV labetalol dose comparison for hemodynamic response to tracheal extubation
IRCT20180416039326N16Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of labetalol (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Systolic blood pressure, Diastolic blood pressure and 3 more. Started Jan 2021; status: completed.
02
Drugs
labetalol
Beyond the preview
Go deeper on IRCT20180416039326N16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180416039326N16.